NCT07163403View on ClinicalTrials.gov

First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

September 20, 2028

Study Completion Date

September 20, 2028

Conditions
Lynch Syndrome
Interventions
BIOLOGICAL

Autologous Tolerogenic Dendritic cells

Autologous peripheral blood differentiated and matured adult dendritic cells loaded with Frameshift-derived neopeptides (FSDN) (DC-DELAY). Eligible participants will receive six intradermal immunizations of DC-DELAY at week 0, 2, 4, 6, 8 and 10.

Trial Locations (1)

08036

Laura Burunat, Barcelona

All Listed Sponsors
lead

Fundacion Clinic per a la Recerca Biomédica

OTHER